Serum inflammatory markers and leukocyte profiles accurately describe hidradenitis suppurativa disease severity

Andriano, Tyler M.; Benesh, Gabrielle; Babbush, Kayla M.; Hosgood, H. Dean; Lin, Juan; Cohen, Steven R.

doi:10.1111/ijd.16244

Cited by 14 publications

(12 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also observed changes in multiple serum biomarkers followingIMTACtherapy.Meanleukocytes,ESR,CRP,and IL-6 decreased, although these values remained above the upperlimitofnormal.Thesefindingsareconsistentwithour recentreportconcerningtheutilityofinflammatorymarkers to follow diseases like HS. 14 Additionally, lower pain scores wereassociatedwithdecreasedleukocytesandCRPlevels, suggestingsubjectivepainmeasuresasapotentialindicator oftheinflammatoryburdenseeninacuteHSflares.Although systemic corticosteroids are characteristically associated with leukocytosis, these effects are short lived, especially following single dose therapy. 25,26 After a mean of 6.77 weeks, we observed decreased leukocyte levels, further corroboratingtheproposedanti-inflammatoryeffectsofIMTAC therapy.…”

Section: Discussionmentioning

confidence: 99%

“…These findings are consistent with our recent report concerning the utility of inflammatory markers to follow diseases like HS. 14 Additionally, lower pain scores were associated with decreased leukocytes and CRP levels, suggesting subjective pain measures as a potential indicator of the inflammatory burden seen in acute HS flares. Although systemic corticosteroids are characteristically associated with leukocytosis, these effects are short lived, especially following single dose therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Exuberant inflammation observed during acute flares typically parallels elevated serum biomarkers of HS severity. 11 -14 Adoption of intralesional triamcinolone acetonide (ILTAC), a widely used injectable corticosteroid, is effective in mitigating acute inflammation and improving quality of life measures. 15,16 Despite the efficacy of ILTAC for acute HS flares, intralesional administration is unworkable for extensive disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Patient Satisfaction Associated With Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background A lack of consensus exists regarding acute flare management in hidradenitis suppurativa (HS). Intramuscular triamcinolone (IMTAC) therapy is useful in numerous inflammatory conditions; however, it has not been investigated for acute HS flares. Objective To evaluate the efficacy and patient experience associated with IMTAC therapy for acute, severe HS flares. Methods Retrospective analysis and surveys of 45 HS patients were conducted at Albert Einstein College of Medicine/ Montefiore HS Center, Bronx, NY, USA. Results Follow-up visits 6.77 (4.45) weeks after IMTAC therapy revealed significant reductions in mean HS-Physician Global Assessment (PGA) ( P < .001), C-Reactive Protein (CRP) ( P = .03), increased hemoglobin ( P = .004), and improved pain scores ( P < .001). Adjusting for age, sex and concomitant medications, multivariate analysis yielded significantly reduced pain ( P = .02) and increased hemoglobin ( P = .03). Patient surveys indicate that IMTAC was well-tolerated, as reflected in positive mean responses for satisfaction (29 [64%]) and willingness to receive IMTAC injections again (42 [93%]). Conclusions These novel findings demonstrate that IMTAC is a safe, effective, and well accepted adjunct for acute HS management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Patient Satisfaction Associated With Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…NRS‐Pain Scores, ranging from 1–10, have been found to be strongly correlated with disease severity 19 . Additionally, inflammatory markers (ESR, CRP, and IL‐6) have been shown to reflect the activity of the clinical disease, correlating with severity (HS‐PGA) over time 20 …”

Section: Discussionmentioning

confidence: 99%

Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Adalimumab is the only FDA‐approved biologic for hidradenitis suppurativa (HS). In the setting of increasing obesity rates worldwide, the relationship between adalimumab efficacy for HS and BMI is essential to understand. We assessed this relationship through markers of disease severity and inflammation. Methods Institutional review board‐approved retrospective chart review of Montefiore/Einstein HS Center (HSC) patients (n = 57) treated with adalimumab. The relationship between BMI and adalimumab efficacy was assessed through disease severity (HS‐Physician Global Assessment [HS‐PGA] 0 and Numerical Rating Scale Pain [NRS‐Pain]) and inflammatory markers (erythrocyte sedimentation rate [ESR], C‐reactive protein [CRP], and interleukin‐6 [IL‐6]). A BMI ≥ 30 is defined as obese; BMI < 30 is defined as non‐obese. Results The mean age was 35.8 ± 13.0 years. After adalimumab therapy, those with BMI < 30 experienced significant reductions in HS‐PGA (−1.5 ± 0.9; P < 0.0001) and NRS‐Pain (−1.6 ± 2.1; P < 0.0001), as well as mean decreases in inflammatory markers ESR, CRP, and IL‐6 (−17.90 ± 23.6, −0.71 ± 1.4, −5.88 ± 7.9, respectively; P > 0.05). Obese patients (BMI ≥ 30) experienced mean increases in HS‐PGA (+0.22 ± 0.8; P > 0.05) and NRS‐Pain scores (+1.41 ± 3.5; P > 0.05) as well as mean increases in ESR, CRP, and IL‐6 (+2.62 ± 28.3, +0.44 ± 3.0, +2.35 ± 6.9, respectively; P > 0.05). Comparing the cohorts, differences in changes in HS‐PGA, NRS‐Pain, ESR, and IL‐6 after therapy are significantly different (P < 0.05). Conclusions We identified significantly lower efficacy of adalimumab in HS patients with BMI ≥ 30 compared to those with BMI < 30. Those with BMI ≥ 30 demonstrated signs of both clinical and physiological deterioration while on adalimumab. Future studies are needed to examine adalimumab dosing for HS patients with high BMI, as well as a critical reconsideration of weight‐based therapies.

show abstract

“…Recently, several molecules and inflammatory markers, such as retinol-binding protein 4 (RBP4), angiopoietin-2 (Ang-2), neutrophil-lymphocyte ratio (NLR), and pan-immune-inflammation value (PIV), were identified as biomarkers of disease severity in patients with HS [ 5 , 6 , 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Angiopoietin-like 2 Protein and Hidradenitis Suppurativa: A New Biomarker for Disease Severity

et al. 2023

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory disease whose pathogenesis is not fully understood at present. The role of proinflammatory cytokines, several adipokines, retinol-binding protein 4, angiopoietin-2 and other molecules has been previously reported. Angiopoietin-like 2 protein (ANGPTL2) is a glycoprotein belonging to the angiopoietin-like family that may play a pivotal role in the pathogenesis of several chronic inflammatory diseases. To our knowledge, the role of serum ANGPTL2 levels in HS has not been assessed to date. In the current case–control study, we aimed to investigate serum ANGPTL2 levels in HS patients and controls and to assess whether ANGPTL2 levels could be associated with the severity of HS. Ninety-four patients with HS and sixty controls of similar age and sex were included in the study. Demographic, anthropometric, and clinical data, as well as routine laboratory parameters and serum concentrations of ANGPTL2, were assessed in all participants. HS patients had significantly higher serum ANGPTL2 levels than controls after adjusting for confounders. Moreover, ANGPTL2 concentrations positively correlated with disease duration and severity. Our results indicate for the first time that serum ANGPTL2 concentrations are elevated in HS patients compared to controls and correlate with the duration of the disease. Besides, ANGPTL2 might serve as a biomarker of HS severity.

show abstract

Serum inflammatory markers and leukocyte profiles accurately describe hidradenitis suppurativa disease severity

Cited by 14 publications

References 49 publications

Efficacy and Patient Satisfaction Associated With Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa

Efficacy and Patient Satisfaction Associated With Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa

Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa

Angiopoietin-like 2 Protein and Hidradenitis Suppurativa: A New Biomarker for Disease Severity

Contact Info

Product

Resources

About